Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab

Clinical and Experimental Rheumatology

Volumn 24, Issue 1, 2006, Pages 38-44

  Dain, Lena ^a   Braun Moscovici, Yolanda ^a   Baum, Elena ^a   Nahir, A Menahem ^a   Hoffer, Erica ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Anti tumor necrosis factor ; Infliximab; Neutrophils; Rheumatoid arthritis; Superoxide anion production

Indexed keywords

CYTOCHROME C; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INCUBATION TIME; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEUTROPHILS; SEVERITY OF ILLNESS INDEX; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE;

EID: 33645047410     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-32.
2. BECKHAM JC, CALDWELL DS, PETERSON BL et al.: Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleikin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992; 12: 353-61.
3. FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
4. KLEBANOFF SJ, VADAS MA et al.: Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136: 4220-5.
5. DUSI S, DELLA BIANCA V, DONINI M, NADALINI KA, ROSSI F: Mechanisms of stimulation of the respiratory burst by TNF-in nonadherent neutrophils: its independence of lipidic transmembrane signaling and dependence on protein tyrosine phosphorylation and cytoskeleton. J Immunol 1996; 157: 4615-23.
6. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
7. LIPSKY PE, Van der HEIJDE DM, St CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
8. CHARLES P, ELLIOTT MJ, DAVIS D et al.: Regulation of cytokines, cytokine inhibitors and acute phase proteins following anti-TNF-α, therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-8.
9. EDWARDS SW, HALLETT MB: Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunil Today 1997; 18: 320-4.
10. CENCETTI A. De MARTINO M, GRAZIANI E et al.: Superoxide anion production by circulating polymorphonuclear leucocytes in rheumatoid arthritis. Clin Rheumatol 1990; 9: 51-5.
11. GREENWALD RA: Oxygen radicals, inflammation and arthritis: pathophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991; 20: 219-40.
12. GREENWALD RA, MOAK SA: Degradation of hyaluronic acid by polymorphonuclear leukocytes. Inflammation 1986; 10: 15-30.
13. GREENWALD RA, MOY WW: Inhibition of collagen gelation by action of the superoxide radical. Arthritis Rheum 1979; 22: 251-6.
14. BURKHARDT H, SCHWINGEL M, MENNINGER H, MACARTNEY HW, TSCHESCHE H: Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. Arthritis Rheum 1986; 29: 379-87.
15. McCORD JM: A superoxide-activated chemotactic factor and its role in the inflammatory process. Agents Actions 1980; 10: 522-7.
16. LUNEC J: Free radical mediated aggregation of human IgG stimulates neutrophils to generate superoxide radicals. Agents Actions 1984, 15: 37-8.
17. BAZZICHI L, CIOMPI ML, BETTI L et al.: Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 761-6.
18. LAURINDO IM, MELLO SB, COSSER, MELLI W: Influence of low doses of Methotrexate on superoxide production by polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Rheumatol 1995; 22: 633-8.
19. BRADLEY SM, LE GALLEZ P, THROUGHTON PR, GOOI HC, ASTBURY C, BIRD HA: The effect of sulphasalazine on neutrophils superoxide generation in rheumatoid arthritis. Br J Rheumatol 1997; 36: 530-4.
20. MINTA JO, WILLIAMS MD: Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J Rheumatol 1985; 12: 751-7.
21. MIYACHI Y, YOSHIOKA A, IMAMURA S, NIWA Y: Anti-oxidant effects of gold compounds. Br J Dermatol 1987; 116: 39-46.
22. HURST NP, FRENCH JK, GORJATSCHKO L, BETTS WH: Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol 1988; 15: 23-7.
23. LEVINE PH, HARDIN JC, SCOON KL, KRINSKY NI: Effect of corticosteroids on the production of superoxide and hydrogen peroxide and the appearance of chemiluminescence by phagocytosing polymorphonuclear leukocytes. Inflammation 1981; 5: 19-27.
24. DEN BROEDER AA, WANTEN GJ, OYEN WJ, NABER T, VAN RIEL PL, BARRERA P: Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 232-7.
25. PREVOO ML, Van 'T HOF MA, KUPER HH, Van LEEUWEN MA, Van de PUTTE LB, Van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 1159-61.
26. SZUCS S, VARGA C, EMBER I, KERTAI P: The separation of the granulocytes from different rat strains. A comparative study. J Immunol Methods 1994; 167: 245-51.
27. PICK E, MIZEL D: Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods 1981; 46: 211-26.
28. BUCH M, SETO Y, BINGHAM S et al.: C-Reactive Protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: 42-48.
29. DUREZ P, NZEUSSEU TOUKAP A, LAUWER YS BR et al.: A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004; 63: 1069-74.
30. HIRANO T, AKIRA S, TAGA T, KISHIMOTO T: Biological and clinical aspects of interleukin 6. Immunol Today 1990; 11: 443-9.
31. HIRANO T, MATSUDA T, TURNER M et al.: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur.J Immunol 1988; 18: 1797-801.
32. HOUSSIAU FA, DEVOGELAER JP, Van DAMME J, De DEUXCHAISNES CN, Van SNICK J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
33. KLIMIUK PA, SIERAKOWSKI S, LATOSIEWICZ R et al.: Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 2003; 21: 63-9.
34. FIRESTEIN GS, XU WD, TOWNSEND K et al.: Cytokines in chronic inflammatory arthritis. J Exp Med 1988; 168: 1573-86.
35. WONG GH KASPAR RE, VEHAR G: Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD. EXS 1996; 77: 321-33.
36. NADIF R, JEDLICKA A, MINTZ M, BERTRAND JP, KLEEBERGER S, KAUFFMANN F: Effect of TNF- and LTA polymorphisms on biological markers of response to oxidative stimuli in coal miners: a model of gene-environment interaction. Tumour necrosis factor and lymphotoxin alpha. J Med Genet 2003; 40: 96-103.
37. DOPP JM, SARAFIAN TA, SPINELLA FM, KAHN MA, SHAU H, De VELLIS J: Expression of the p75 TNF- receptor is linked to TNF-induced NfkappaB translocation and oxyradical neutralization in glial cells. Neurochem Res 2002; 27: 1535-42.
38. SCHNEIDER K, POTTER KG, WARE CF: Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004; 202: 49-66.
39. FAVA RA, NOTIDIS E, HUNT J et al.: A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003; 171: 115-26.
40. BUCH MH, CONAGHAN PG, QUINN MA, BINGHAM SJ, VEALE D, EMERY P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha ? Ann Rheum Dis 2004; 63: 1344-6.
41. JONSSON SW, BACKMAN C, JOHNSON O et al.: Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001; 28: 2597-602.
42. KUMEDA Y, INABA M, GOTO H et al.: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-97.
43. GOODSON NJ, SILMAN AJ, PATTISON DJ et al.: Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology 2004; 43: 731-736.